Just as effective as the high dose, low-dose apixaban prevents long-term recurrent venous thromboembolism in patients with ...

On top of noninferior efficacy, the trial showed patients had less bleeding with 2.5 mg vs 5.0 mg twice daily over 12 months.

For extended anticoagulation after venous thromboembolism (VTE) in patients with active cancer, a lower dose of apixaban ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

Summary Apixaban is an oral ... regimen in clinical trials without the need for anticoagulation monitoring or dosage adjustment. Apixaban has multiple elimination pathways, and its ...

Results show noninferiority to a full dose in preventing a recurrence of blood clots and an advantage when it comes to ...

To the Editor: Inhibition of factor XI or activated factor XI (XIa) should provide protection against stroke with a low risk of bleeding, given that the incidence of bleeding or adverse ...

In 2021, the American College of Chest Physicians released clinical guidelines that suggested reduced dosage of either apixaban or rivaroxaban for extended management of blood clots, noting this ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least ...

This means apixaban cut the clot risk by nearly half. It also improved the chances of keeping the vascular access working without further issues (32% failure rate versus 50% in the control group).